Werewolf Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 7, 2024

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity for the and

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(amounts in thousands, except share amounts)

Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance at December 31, 2023	39,107,048	$4	$455,443	$(344,073)		$111,374
Issuance of common stock from at the market offering, net of issuance costs of $985	4,169,324	—	20,089	—		20,089
Stock-based compensation expense	—	—	2,305	—		2,305
Stock option exercises	5,999	—	12	—		12
Net loss	—	—	—	(16,193)		(16,193)
Balance at March 31, 2024	43,282,371	4	477,849	(360,266)		117,587
Issuance of common stock from at the market offering, net of issuance costs of $61	172,996	—	1,002	—		1,002
Issuance of common stock, net	246,680	—	76	—		76
Stock-based compensation expense	—	—	2,602	—		2,602
Stock option exercises	100	—	—	—		—
Net loss	—	—	—	(17,249)		(17,249)
Balance at June 30, 2024	43,702,147	4	481,529	(377,515)		104,018
Issuance of common stock from at the market offering, net of issuance costs of $50	8,500	—	—	—		—
Stock-based compensation expense	—	—	2,011	—		2,011
Stock option exercises	11,125	—	23	—		23
Net loss	—	—	—	(16,673)		(16,673)
Balance at September 30, 2024	43,721,772	$4	$483,563	$(394,188)		$89,379
Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balance at December 31, 2022	31,515,074	$3	$429,039	$(306,705)		$122,337
Issuance of common stock from at the market offering, net of issuance cost of $103	3,824,249	—	8,610	—		8,610
Stock-based compensation expense	—	—	2,108	—		2,108
Net loss	—	—	—	(11,982)		(11,982)
Balance at March 31, 2023	35,339,323	3	439,757	(318,687)		121,073
Issuance of common stock from at the market offering, net of issuance costs of $31	272,032	—	644	—		644
Issuance of common stock, net	28,739	—	45		45
Stock-based compensation expense	—	—	1,930	—		1,930
Stock option exercises	1,690	—	5	—		5
Net loss	—	—	—	(5,098)		(5,098)
Balance at June 30, 2023	35,641,784	3	442,381	(323,785)		118,599
Issuance of common stock from at the market offering, net of issuance costs of $29	15,000	—	30	—		30
Stock-based compensation expense	—	—	2,097	—		2,097
Stock option exercises	1,266	—	2	—		2
Net loss	—	—	—	(8,285)		(8,285)
Balance at September 30, 2023	35,658,050	$3	$444,510	$(332,070)		$112,443

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.